Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 304032, 7 pages
http://dx.doi.org/10.1155/2014/304032
Clinical Study

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide

1Diabetes and Obesity Center, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece
2Biochemistry Laboratory, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece
31st Department of Propaedeutic and Internal Medicine, Laiko General Hospital, Athens University Medical School, 17 Agiou Thoma Street, 115 27 Athens, Greece

Received 4 July 2014; Accepted 5 July 2014; Published 4 August 2014

Academic Editor: Nikolaos Papanas

Copyright © 2014 Maria Voukali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Zimmet, K. G. M. M. Alberti, and J. Shaw, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M.-R. Taskinen, “Diabetic dyslipidaemia: from basic research to clinical practice,” Diabetologia, vol. 46, no. 6, pp. 733–749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. R. H. J. Bandsma and G. F. Lewis, “Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia,” Atherosclerosis, vol. 212, no. 1, pp. 40–41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. B. G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen, “Nonfastingtriglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women,” JAMA, vol. 298, no. 3, pp. 299–308, 2007. View at Google Scholar
  5. F. Karpe, “Postprandial lipoprotein metabolism and atherosclerosis,” Journal of Internal Medicine, vol. 246, no. 4, pp. 341–355, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Carstensen, C. Thomsen, O. Gotzsche, J. J. Holst, J. Schrezenmeir, and K. Hermansen, “Differential postprandial lipoprotein responses in type 2 diabetic menwith and without clinical evidence of a former myocardial infarction,” The Review of Diabetic Studies, vol. 1, no. 4, pp. 175–184, 2004. View at Google Scholar
  7. G. F. Lewis, “Postprandial lipoprotein metabolism in diabetes mellitus and obesity,” Journal of Atherosclerosis and Thrombosis, vol. 2, supplement 1, pp. S34–S35, 1995. View at Google Scholar
  8. K. Adeli and G. F. Lewis, “Intestinal lipoprotein overproduction in insulin resistant states,” Current Opinion in Lipidology, vol. 19, pp. 221–228, 2008. View at Publisher · View at Google Scholar
  9. D. J. Drucker, “The biology of incretin hormones,” Cell Metabolism, vol. 3, no. 3, pp. 153–165, 2006. View at Google Scholar
  10. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Vilsbøll, M. Christensen, A. E. Junker, F. K. Knop, and L. L. Gluud, “Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials,” The BMJ, vol. 344, no. 7841, Article ID d7771, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. J. Meier and M. A. Nauck, “Glucagon-like peptide 1(GLP-1) in biology and pathology,” Diabetes/Metabolism Research and Reviews, vol. 21, no. 2, pp. 91–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Drucker, “Enhancing incretin action for the treatment of type 2 diabetes,” Diabetes Care, vol. 26, no. 10, pp. 2929–2940, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Holst, “Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors,” Expert Opinion on Emerging Drugs, vol. 9, no. 1, pp. 155–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. Meier, A. Gethmann, O. Götze et al., “Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans,” Diabetologia, vol. 49, no. 3, pp. 452–458, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Blonde and D. Russell-Jones, “The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies,” Diabetes, Obesity and Metabolism, vol. 11, supplement 3, pp. 26–34, 1987. View at Publisher · View at Google Scholar
  18. C. Mihas, G. D. Kolovou, D. P. Mikhailidis et al., “Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis,” Current Vascular Pharmacology, vol. 9, no. 3, pp. 271–280, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. L. S. Mortensen, M. L. Hartvigsen, L. J. Brader et al., “Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein,” The American Journal of Clinical Nutrition, vol. 90, no. 1, pp. 41–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Tremblay, B. Lamarche, C. F. Deacon, S. J. Weisnagel, and P. Couture, “Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 366–373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Matikainen, S. Mänttäri, A. Schweizer et al., “Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes,” Diabetologia, vol. 49, no. 9, pp. 2049–2057, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Schwartz, J. Koska, M. P. Mullin, I. Syoufi, D. C. Schwenke, and P. D. Reaven, “Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus,” Atherosclerosis, vol. 212, no. 1, pp. 217–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Koska, E. A. Schwartz, M. P. Mullin, D. C. Schwenke, and P. D. Reaven, “Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes,” Diabetes Care, vol. 33, no. 5, pp. 1028–1030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. L. Schwartz, R. E. Ratner, D. D. Kim et al., “Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study,” Clinical Therapeutics, vol. 30, no. 5, pp. 858–867, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Hermansen, T. A. Bækdal, M. Düring et al., “Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial,” Diabetes, Obesity and Metabolism, vol. 15, no. 11, pp. 1040–1048, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. D. R. Owens, L. Monnier, and G. B. Bolli, “Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus,” Diabetes & Metabolism, vol. 39, no. 6, pp. 485–96, 2013. View at Publisher · View at Google Scholar
  27. J. J. Meier, B. Gallwitz, S. Salmen et al., “Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2719–2725, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Wettergren, B. Schjoldager, P. E. Mortensen, J. Myhre, J. Christiansen, and J. J. Holst, “Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man,” Digestive Diseases and Sciences, vol. 38, no. 4, pp. 665–673, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Nauck, U. Niedereichholz, R. Ettler et al., “Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans,” American Journal of Physiology-Endocrinology and Metabolism, vol. 273, no. 5, pp. E981–E988, 1997. View at Google Scholar · View at Scopus
  30. M. A. Nauck, G. Kemmeries, J. J. Holst, and J. J. Meier, “Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans,” Diabetes, vol. 60, no. 5, pp. 1561–1565, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Wettergren, M. Wøjdemann, and J. J. Holst, “Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 275, no. 5, pp. G984–G992, 1998. View at Google Scholar · View at Scopus
  32. Y. M. Cho, R. D. Wideman, and T. J. Kieffer, “Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus,” Endocrinology and Metabolism, vol. 28, no. 4, pp. 262–274, 2013. View at Publisher · View at Google Scholar
  33. D. J. Drucker, J. B. Buse, K. Taylor et al., “Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study,” The Lancet, vol. 372, no. 9645, pp. 1240–1250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. B. Buse, A. Garber, J. Rosenstock et al., “Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 6, pp. 1695–1702, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Jelsing, N. Vrang, G. Hansen, K. Raun, M. Tang-Christensen, and L. Bjerre Knudsen, “Liraglutide: Short-lived effect on gastric emptying-long lasting effects on body weight,” Diabetes, Obesity and Metabolism, vol. 14, no. 6, pp. 531–538, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Kapitza, M. Zdravkovic, C. Hindsberger, and A. Flint, “The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen,” Advances in Therapy, vol. 28, no. 8, pp. 650–660, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Horowitz, A. Flint, K. L. Jones et al., “Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 97, no. 2, pp. 258–266, 2012. View at Publisher · View at Google Scholar · View at Scopus